Insider Transactions in Q4 2021 at Flexion Therapeutics Inc (FLXN)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2021
|
Newtyn Management, LLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,900,000
-100.0%
|
-
|
|
Nov 19
2021
|
Michael D. Clayman President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
787,052
-100.0%
|
$6,296,416
$8.5 P/Share
|
|
Nov 19
2021
|
Michael D. Clayman President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
335,498
-100.0%
|
$2,683,984
$8.5 P/Share
|
|
Nov 19
2021
|
William T. Andrews Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
34,250
-100.0%
|
$274,000
$8.5 P/Share
|
|
Nov 19
2021
|
Frederick W Driscoll Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,680
-100.0%
|
$245,440
$8.5 P/Share
|
|
Nov 19
2021
|
Christina Willwerth Chief Strategy Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
141,241
-100.0%
|
$1,129,928
$8.5 P/Share
|
|
Nov 19
2021
|
Melissa Layman Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,956
-100.0%
|
$831,648
$8.5 P/Share
|
|
Nov 19
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,000
-100.0%
|
$48,000
$8.5 P/Share
|
|
Nov 19
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
140,843
-100.0%
|
$1,126,744
$8.5 P/Share
|
|
Nov 19
2021
|
Adam Muzikant Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,666
-100.0%
|
$829,328
$8.5 P/Share
|
|
Nov 19
2021
|
Mark S. Levine General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
133,486
-100.0%
|
$1,067,888
$8.5 P/Share
|
|
Nov 19
2021
|
Patrick J Mahaffy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,824
-100.0%
|
$318,592
$8.5 P/Share
|
|
Nov 19
2021
|
Scott A Canute Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
Samuel D Colella Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,487,564
-100.0%
|
$11,900,512
$8.5 P/Share
|
|
Nov 19
2021
|
Samuel D Colella Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
Elizabeth Kwo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,500
-100.0%
|
$36,000
$8.5 P/Share
|
|
Nov 19
2021
|
Heath Lukatch Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
C Ann Merrifield Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,000
-100.0%
|
$152,000
$8.5 P/Share
|
|
Nov 19
2021
|
Alan Milinazzo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,450
-100.0%
|
$219,600
$8.5 P/Share
|
|
Nov 19
2021
|
Mark Stejbach Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,631
-100.0%
|
$101,048
$8.5 P/Share
|